268

Bioinformatics of the Brain

[48] L. Higginbotham, L. Ping, E. B. Dammer, et al., “Integrated pro-

teomics reveals brain-based cerebrospinal fluid biomarkers in asymp-

tomatic and symptomatic alzheimer’s disease,” Science advances, vol. 6,

no. 43, p. eaaz9360, 2020.

[49] G. Sathe, C. H. Na, S. Renuse, et al., “Quantitative proteomic profiling

of cerebrospinal fluid to identify candidate biomarkers for alzheimer’s

disease,” PROTEOMICS–Clinical Applications, vol. 13, no. 4, p. 1800105,

2019.

[50] K. E. Wesenhagen, C. E. Teunissen, P. J. Visser, et al., “Cerebrospinal

fluid proteomics and biological heterogeneity in alzheimer’s disease: a

literature review,” Critical reviews in clinical laboratory sciences, vol. 57,

no. 2, pp. 86–98, 2020.

[51] K. K. Dey, H. Wang, M. Niu, et al., “Deep undepleted human serum

proteome profiling toward biomarker discovery for alzheimer’s disease,”

Clinical proteomics, vol. 16, no. 1, pp. 1–12, 2019.

[52] H. Wang, K. K. Dey, P.-C. Chen, et al., “Integrated analysis of ultra-

deep proteomes in cortex, cerebrospinal fluid and serum reveals a mito-

chondrial signature in alzheimer’s disease,” Molecular neurodegeneration,

vol. 15, no. 1, pp. 1–20, 2020.

[53] K. K. Dey, H. Sun, Z. Wang, et al., “Proteomic profiling of cerebrospinal

fluid by 16-plex tmt-based mass spectrometry,” Clinical proteomics:

Methods and protocols, pp. 21–37, 2022.

[54] E. Eldem, A. Barve, O. Sallin, et al., “Salivary proteomics identifies

transthyretin as a biomarker of early dementia conversion,” Journal of

Alzheimer’s Disease Reports, vol. 6, no. 1, pp. 31–41, 2022.

[55] K. McNicholas, M. François, J.-W. Liu, et al., “Salivary inflammatory

biomarkers are predictive of mild cognitive impairment and alzheimer’s

disease in a feasibility study,” Frontiers in Aging Neuroscience, vol. 14,

p. 1019296, 2022.

[56] F. Yao, X. Hong, S. Li, et al., “Urine-based biomarkers for alzheimer’s dis-

ease identified through coupling computational and experimental meth-

ods,” Journal of Alzheimer’s Disease, vol. 65, no. 2, pp. 421–431, 2018.

[57] M. Inoue, H. Suzuki, K. Meno, et al., “Identification of plasma proteins as

biomarkers for mild cognitive impairment and alzheimer’s disease using

liquid chromatography–tandem mass spectrometry,” International Jour-

nal of Molecular Sciences, vol. 24, no. 17, p. 13064, 2023.

[58] M. Aroso, R. Ferreira, A. Freitas, et al., “New insights on the mito-

chondrial proteome plasticity in parkinson’s disease,” PROTEOMICS–

Clinical Applications, vol. 10, no. 4, pp. 416–429, 2016.